Delivery Order 36F79724D0176-36C24525N0190
Award Date
11/20/24
Potential Completion Date
11/22/24
Potential Value
$14K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Janssen Biotech Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Carrollton, TX 75010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide BALVERSA (erdafitinib), an oncology medication, to the VA's Veterans Health Administration (VHA). The $15,090.62 delivery order was issued on an emergency basis to the pharmaceutical manufacturer under a $3.7 million Blanket Purchase Agreement (BPA) established in 2020, which allows VHA buying offices to efficiently...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide the chemotherapy drug BALVERSA (erdafitinib) for patient care. The $17,642.94 delivery order was issued against Janssen's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has a period of performance through May 7, 2024 and was awarded on May 2,...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the supply of the chemotherapy drug BALVERSA (erdafitinib). This order is issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs. The potential value of this specific...
This federal contract award was issued by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a prominent pharmaceutical manufacturer. The $18,803.91 firm fixed price delivery order is for the oncology medication BALVERSA 4 MG, with a completion date of June 6, 2025. The award is part of a larger $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) held by Janssen Biotech Inc. with...
This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the delivery of BALVERSA (erdafitinib), a cancer treatment drug, to the U.S. Department of Veterans Affairs (VA). The contract is a Blanket Purchase Agreement (BPA) with a ceiling value of $45,271.88 and a period of performance through January 31, 2022. This BPA was established in March 2021 under the VA's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), a...
This federal contract award is for BALVERSA (erdafitinib), an oncology medication, provided by Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.) to the Department of Veterans Affairs (VA). The $11,317.97 firm fixed price contract is a Blanket Purchase Agreement (BPA) call order under Janssen's $3.7 million single-award BPA established in August 2020, which allows VA buying offices to efficiently procure BALVERSA and other oncology drugs. Janssen also holds a $3.1 billion...
This is a firm fixed price delivery order awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The order is against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with a ceiling value of $17,642.95. The contract is for the chemotherapy drug BALVERSA 4 MG to support healthcare services for veterans. This delivery order is part of a larger $3.1 billion...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs Veterans Health Administration to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order, valued at $62,248.81, is for the cancer treatment drug BALVERSA to support healthcare services for veterans. The delivery order was issued under Janssen's General Services Administration Multiple Award Schedule Contract for Pharmaceuticals and Drugs (FSS-61-IB), which allows the VA to efficiently...
This is a delivery order contract awarded by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a major pharmaceutical manufacturer. The $13,639.07 firm fixed price contract is for the delivery of BALVERSA 3 MG, an oncology medication, to support the VA's Veterans Health Administration (VHA) and its Veterans Integrated Service Networks (VISNs). Janssen Biotech holds several significant federal contracts with the VA, including a $3.1...